When it comes to smoothing out fine lines and wrinkles, two popular names often come up: Jeuveau and Botox. Botox is the OG in the neuromodulator space, and Jeuveau is the up-and-coming, trendy newer treatment. But how do these wrinkle-relaxing injectables compare? And which one should you choose?
If you’re looking for a safe, effective way to refresh your look without surgery, this article will walk you through the key differences, similarities, and everything in between when it comes to Jeuveau vs Botox.
What Are Jeuveau and Botox?
Both Jeuveau and Botox are injectable treatments made from botulinum toxin type A. They are both a part of the neuromodular class of skincare ingredients that are used in aesthetics to help prevent and erase the signs of aging. Neuromodulators are ingredients that work by temporarily relaxing muscles that cause wrinkles, especially in areas like the forehead, between the eyebrows (glabellar lines), and around the eyes (crow’s feet).
When neuromodulators stop these muscles from contracting as strongly, the skin appears smoother and more youthful. They can be used after lines and wrinkles form, or they can be used preventatively.
Jeuveau vs Botox: Quick Comparison
| Feature | Jeuveau | Botox |
|---|---|---|
| FDA Approval | 2019 (cosmetic use only) | 2002 (cosmetic + medical use) |
| Main Use | Aesthetic treatment of wrinkles | Aesthetic & medical treatments |
| Onset of Results | ~2–3 days | ~3–4 days |
| Duration of Results | 3–4 months (up to 6 in high doses) | 3–4 months |
| Cost per Unit | ~20–25% less than Botox | Typically higher |
| Common Side Effects | Mild headache, injection site bruising | Same as Jeuveau |
| Unique Feature | Made exclusively for beauty use | Used for both beauty and medical issues |
So, How Are Jeuveau and Botox Alike?
From a scientific perspective, Jeuveau and Botox are nearly identical. Both skincare treatments:
- Use botulinum toxin A to stop muscle contractions
- Have the same dosing for effective results (20 units for frown lines)
- Are injected into similar facial muscles
- Offer temporary wrinkle smoothing
- Last up to 3 to 4 months for most people
In head-to-head clinical studies, Jeuveau matched Botox in both safety and wrinkle-reducing power, with 87% of Jeuveau users and 83% of Botox users seeing visible improvement in frown lines by Day 30. Even for crow’s feet (the little lines around your eyes), Jeuveau performed just as well as Botox in a split-face trial, showing similar results.
What Makes Jeuveau Different?
1. Aesthetic-Only Focus
Jeuveau is the first neurotoxin designed solely for cosmetic use. It doesn’t have medical approvals like Botox does for migraines or muscle spasms. This singular focus allows its manufacturer to keep pricing competitive and marketing tailored for beauty use. In my opinion, it also means they were able to focus on features that are important to beauty enthusiasts, like faster acting and limiting side effects from long-term usage.
2. Cost Advantage
Because Jeuveau isn’t part of a broader medical portfolio, it’s often 20–25% less expensive than Botox for the same treatment. For people doing regular touch-ups every few months, that adds up to real savings over time. Or if you are someone wanting to give it a try for the first time, this offers you a lower-cost entry point to the treatment.
3. Purity Process
Jeuveau is made with a high-purity method called “Hi-Pure,” which may reduce inactive proteins in the formula. This could potentially lower the (already low) risk of building resistance after repeated use associated with some other neuromodulators.
What About Results? Are the Differences Between Jeuveau vs. Botox?
Both Jeuveau and Botox deliver fast, noticeable results, but some studies show Jeuveau may kick in slightly faster. In clinical studies, results from Jeuveau were typically seen in 2-3 days compared to 3-4 days for Botox. Specifically, one study comparing four toxins, Jeuveau showed one of the quickest onsets of muscle relaxation effects by Day 3. For anyone seeking results before a big event, this could be a small but meaningful advantage.
How Long Do Results Last?
For most people, for both Jeuveau and Botox, the results lasted largely the same amount of time. Both last roughly 3-4 months at standard dosages and up to 6 months at higher dosages. Ultimately, everyone’s results are very personalized, and you could experience different results.
Who If Jeuveau Best For Compared To Botox?
Everyone can benefit from both of these treatments, but Jeuveau showed higher satisfaction among younger users (especially millennials). In trials, 97% of patients under 40 saw visible results, compared to 85% in older groups.
This makes Jeuveau a strong choice for people in their 20s and 30s who are starting preventative treatments early to prevent the formation of fine lines and wrinkles.
Jeuveau vs Botox: So Which One Should You Choose?
Ultimately, talk with your skincare provider about what treatment should be your final step before you pursue any treatment. However, here are some general guidelines you could use a conversation starters and thought provokers on which make the most sense for you:
| If You Want… | Choose… |
|---|---|
| A trusted brand with medical uses | Botox |
| A cost-effective, beauty-focused option | Jeuveau |
| Faster onset and high satisfaction in younger users | Jeuveau |
| To stick with what’s widely known | Botox |
Both treatments are backed by clinical research, FDA-approved, and considered very safe when performed by trained professionals.
Are There Any Risks?
The risks are nearly the same for both. The most common side effects include:
- Mild headache
- Bruising at the injection site
- Temporary eyelid drooping (rare, ~1–2%)
- Mild redness or swelling
These effects are typically mild and resolve on their own. No serious safety concerns have been linked to either product when used cosmetically.
So, What is the Final Verdict On Jeuveau vs Botox
When comparing Jeuveau vs Botox, there’s no one-size-fits-all answer. Both offer reliable, science-backed wrinkle reduction. The right choice comes down to your goals, your budget, and your provider’s recommendation.
References
Beer, K.R., Shamban, A.T., Avelar, R.L., Gross, J.E., & Jonker, A. (2019). Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery, 45(12), 1381-1393. DOI: 10.1097/DSS.0000000000001903
Cheon, H.I., Jung, N., Won, C.H., Kim, B.J., & Lee, Y.W. (2019). Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow’s feet: a phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery, 45(12), 1610-1619. DOI: 10.1097/DSS.0000000000001920
Rzany, B.J., Ascher, B., Avelar, R.L., et al. (2020). A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase 3, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthetic Surgery Journal, 40(4), 413-429. DOI: 10.1093/asj/sjz110
Gadarowski, M.B., Ghamrawi, R., Taylor, S.L., & Feldman, S.R. (2021). PrabotulinumtoxinA-xvfs for the treatment of moderate-to-severe glabellar lines: a review of phase II and III clinical trials. Annals of Pharmacotherapy, 55(3), 279-287. DOI: 10.1177/1060028020943527
Avelar, R.L. (2024). Post hoc analysis comparing the safety and efficacy of prabotulinumtoxinA in millennials and nonmillennials with moderate to severe glabellar lines. Dermatologic Surgery, 50(9 Suppl), S42–S47. DOI: 10.1097/DSS.0000000000004249
Lemdani, M.S., Honig, S.E., Habarth-Morales, T.E., et al. (2025). Comparison of botulinum toxin A formulations for glabellar strain treatment in women: a double-blind randomized clinical trial. JAMA Dermatology, 161(7), 723-730. DOI: 10.1001/jamadermatol.2025.1335
Jung, B.K., Park, H., Cheon, Y.W., et al. (2023). Clinical investigation of botulinum toxin (prabotulinumtoxin A) for bruxism related to masseter muscle hypertrophy: a prospective study. Journal of Cranio-Maxillofacial Surgery, 51(5), 332-337. DOI: 10.1016/j.jcms.2023.05.005
Fagien, S., Avelar, R.L., Cox, S.E., Joseph, J.H., Kaufman-Janette, J., & Marcus, K.A. (2024). Safety and duration of effect of 40-unit prabotulinumtoxinA-xvfs for the treatment of moderate to severe glabellar lines in adult patients: a phase II, multicenter, randomized, double-blind, active-controlled trial. Aesthetic Surgery Journal, 44(9), 987-1000. DOI: 10.1093/asj/sjae051
Clifton, M. (2023). PrabotulinumtoxinA-xvfs (Jeuveau, Evolus) for the temporary treatment of glabellar lines: what does this toxin bring to the table? The Dermatology Digest.
European Medicines Agency. (2019). Nuceiva (botulinum toxin type A) – EPAR Product Information. EMA/249428/2019. (Available at EMA website).